Journal of Capital Medical University ›› 2017, Vol. 38 ›› Issue (2): 308-312.doi: 10.3969/j.issn.1006-7795.2017.02.028

Previous Articles     Next Articles

Clinical study on circulating VCAM-1 to evaluate the metastasis risk of mastoscopic axillary lymph node dissection

Luo Chengyu, Fan Kemin, Ge Shasha, Cui Zhimiao   

  1. Breast Minimally Invasive Center, Fuxing Hospital, Capital Medical University, Beijing 100038, China
  • Received:2016-12-26 Online:2017-03-21 Published:2017-04-17
  • Supported by:
    This study was supported by Study of the Application of Clinical Characteristics of Capital (Z131107002213145)

Abstract: Objective To elucidate the change after mastoscopic axillary lymph node dissection (MALND) and conventional axillary lymph node dissection (CALND) and further prove the safety of MALND.Methods 104 breast cancer patients (January 1st, 2014 to July 31 st, 2015) from Breast Minimally Invasive Center, Fuxing Hospital,Capital Medical University who were undergone ALND were randomly divided into two groups:CALND(n=52) and MALND(n=52). The peripheral blood samples were respectively collected in pre-operation and 1,3,5 days after operation. The circulating levels of vascular cell adhesion molecular-1 (VCAM-1) in blood were analyzed by ELISA. Results Circulating VCAM-1 levels of CALND group on postoperative 1 d(51.74±1.37)ng/mL,3 d(52.64±1.24)ng/mL,5 d(52.22±1.29)ng/mL decreased significantly than that of pre-operation (56.56±1.24)ng/mL. And the figures of MALND group turn to be(53.24±1.21)ng/mL,(52.07±1.34)ng/mL,(48.99±1.27)ng/mL,(58.66±0.95) ng/mL. The VCAM-1 levels of MALND group is lower than that of CALND, but there was no statistical difference between the two groups (P>0.05). Conclusion The change of circulating VCAM-1of patients after MALND is same to that of CALND. There is no evidence that MALND increases the risk of blood dissemination of tumor.

Key words: breast cancer, mastoscopic axillary lymph node dissection(MALND), vascular cell adhesion molecular-1 (VCAM-1)

CLC Number: